Company Overview
Cue Biopharma, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing a novel class of injectable therapeutics designed to selectively engage and modulate targeted, disease-relevant T cells within the United States. The company functions within the healthcare sector, specifically inside the biotechnology industry, which implies a focus on early-stage research and development of biological products rather than established manufacturing or commercialization of finished goods. This entity maintains a modest scale characterized by a market capitalization of $23.38M, annual revenue of $27.47M, and a workforce of 29 employees. These financial figures indicate that the company operates with a very small balance sheet and a lean organizational structure typical of pre-commercial biotech firms, suggesting that its primary value proposition currently resides in intellectual property and pipeline potential rather than operational cash flow or established market share.
Financial Health
The company reported revenue of $27.47M over the trailing twelve months, yet it recorded a net income of -$26,602,000 and an EBITDA of -$25,563,000, revealing a significant gap between top-line generation and bottom-line profitability that highlights a cost structure dominated by research and development expenses. Free cash flow stands at -$9,951,750, which indicates that the company is consuming cash reserves to fund its operations and drug development efforts rather than generating surplus liquidity for debt repayment or shareholder returns. The company's margin profile presents a complex picture, with a gross margin of -26.9%, an operating margin of 8.9%, and a profit margin of -96.9%. The negative gross margin suggests that the cost of goods sold exceeds revenue in the current accounting period, while the positive operating margin amidst negative net income points to non-operating expenses or interest costs driving the overall loss. The balance sheet shows a cash position of $28.23M against total debt of $4.20M, supported by a debt-to-equity ratio of 15.88, indicating a leveraged capital structure where debt obligations are substantial relative to equity. Despite the leverage, the current ratio of 2.74 suggests that the company holds sufficient current assets to cover its short-term liabilities, providing a buffer against immediate liquidity pressures. Return on Equity is -121.1% and Return on Assets is -44.6%, metrics that reveal that management is currently utilizing shareholder capital and total assets to generate losses rather than returns, a common but high-risk characteristic of clinical-stage ventures awaiting product approval.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to the negative earnings, while the forward P/E is listed as -0.50, implying that the market is pricing in expectations of future earnings that differ significantly from current historical performance metrics. The price-to-book ratio is 0.87, indicating that the market values the company at a slight discount to its net asset value, which is often seen in biotechnology firms where intangible assets like patents are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 0.85 and an EV/EBITDA of 0.03 suggest that the company is valued based on revenue multiple expansion potential rather than earnings power, given the lack of profitability. The stock has exhibited significant volatility, trading between a 52-week low of $0.22 and a 52-week high of $1.05. Without the current share price explicitly provided in the source facts, the precise percentage deviation from these bounds cannot be calculated, but the range itself highlights the speculative nature of the investment. The beta value of 1.55 indicates that the stock's price volatility is 55% higher than the broader market, meaning it tends to amplify market movements and carries elevated risk for price swings.
Growth & Income
Revenue growth year-over-year is exceptionally high at 1292.3%, while earnings growth is N/A due to the absence of positive net income in the prior period comparison. The discrepancy between massive revenue expansion and continued negative earnings growth implies that the top-line gains are being heavily offset by scaling costs or one-time charges associated with clinical trials. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings (or lack thereof) are being reinvested into the company's growth initiatives rather than distributed to shareholders. The overall growth and income profile is defined by explosive revenue expansion coupled with significant cash consumption and zero dividend income, positioning the asset purely as a capital appreciation play dependent on future clinical milestones.